+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06414954

Evaluating Safety and Effects of Three NMD670 Dose Levels Versus Placebo in Adults With AChRMuSK Antibody-Positive Myasthenia Gravis Over 21 Days

Led by NMD Pharma A/S · Updated on 2026-08-21

84

Participants Needed

40

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of three different doses of the drug NMD670 compared to a placebo in adults with Myasthenia Gravis who have antibodies against AChR or MuSK. This Phase 2 proof-of-concept study aims to find the appropriate dose by assessing how the drug affects muscle strength over 21 days of treatment. Participants will take either a high, mid, or low dose of NMD670 tablets, or placebo tablets, twice daily for 21 days. The study is randomized and double-blinded, meaning neither participants nor researchers know who receives which dose. The goal is to compare the changes in muscle strength and other symptoms between the different dose groups and placebo during this treatment period. During the study, participants will be monitored for changes in muscle strength using the Quantitative Myasthenia Gravis QMG score and other related clinical assessments. Safety will be closely watched through physical exams, lab tests, vital signs, ECGs, and eye exams from screening through follow-up. The study also tracks any adverse events during the 21-day dosing and follow-up period. Participants will be involved in visits and assessments throughout the trial, which is expected to complete by December 2026.

CONDITIONS

Brief Title

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Research Team

N

NMD Pharma A/S

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here